Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review

Area of Science:

• Dermatology
• Immunology

Background:

• Generalized pustular psoriasis (GPP) is a rare, chronic, and potentially life-threatening dermatological condition.
• Current treatments for GPP, often adapted from plaque psoriasis therapies, show limited efficacy and do not address the underlying IL-36 pathway.
• The interleukin-36 (IL-36) pathway is a key factor in GPP pathogenesis.

Purpose of the Study:

• To outline practical considerations for personalizing the treatment of GPP.
• To highlight the importance of targeting the IL-36 pathway in GPP management.

Main Methods:

• Review of current understanding of GPP pathogenesis.
• Analysis of therapeutic strategies targeting the IL-36 pathway.
• Consideration of clinical management approaches for GPP.

Main Results:

• The IL-36 pathway is critically involved in GPP.
• A systemic biologic targeting the IL-36 receptor is the only approved GPP treatment.
• Personalized treatment strategies are essential for optimizing patient outcomes.

Conclusions:

• Targeting the IL-36 pathway represents a significant advancement in GPP treatment.
• Personalized therapeutic approaches are crucial for managing GPP effectively.
• The approved IL-36 receptor antagonist offers a promising option for improving GPP patient care.